Table 2.
Histological assessment of hPCLS
| hPCLS type | Treatment | D1 |
D8 |
D15 |
D22 |
D29 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVE±SD | AVE±SD | AVE±SD | AVE±SD | AVE±SD | |||||||||||||
| H&E | Fresh | VC | 87 | ± | 3 | 78 | ± | 3 | 82 | ± | 3 | 80 | ± | 0 | 73 | ± | 3 |
| LPS | 80 | ± | 9 | 87 | ± | 6 | 83 | ± | 6 | 80 | ± | 0 | 77 | ± | 6 | ||
| Cryo 1 | VC | 83 | ± | 8 | 85 | ± | 5 | 80 | ± | 5 | 80 | ± | 0 | 82 | ± | 8 | |
| LPS | 75 | ± | 9 | 83 | ± | 3 | 80 | ± | 5 | 83 | ± | 3 | 75 | ± | 5 | ||
| Cryo 2 | VC | 60 | ± | 10 | 78 | ± | 3 | 82 | ± | 3 | 80 | ± | 5 | 78 | ± | 3 | |
| LPS | 68 | ± | 8 | 75 | ± | 5 | 75 | ± | 0 | 77 | ± | 6 | 78 | ± | 3 | ||
| AQ5 | Fresh | VC | 197 | ± | 6 | 190 | ± | 0 | 185 | ± | 5 | 177 | ± | 32 | 165 | ± | 18 |
| LPS | 177 | ± | 25 | 203 | ± | 6 | 203 | ± | 6 | 187 | ± | 25 | 178 | ± | 8 | ||
| Cryo 1 | VC | 160 | ± | 42 | 197 | ± | 6 | 197 | ± | 12 | 197 | ± | 6 | 160 | ± | 20 | |
| LPS | 177 | ± | 15 | 217 | ± | 6 | 190 | ± | 26 | 213 | ± | 12 | 173 | ± | 12 | ||
| Cryo 2 | VC | 133 | ± | 25 | 193 | ± | 15 | 203 | ± | 12 | 217 | ± | 6 | 203 | ± | 25 | |
| LPS | 137 | ± | 12 | 197 | ± | 23 | 207 | ± | 6 | 207 | ± | 15 | 177 | ± | 15 | ||
Notes: Evaluation of H&E- and AQ5-stained sections at days 1, 8, 15, 22, and 29 indicates comparable results throughout the ∼4-week culture period. All groups (Fresh, Cryo 1, and Cryo 2) yielded ≥75% “normal” morphological characteristics (H&E) for both VC- and LPS-treated hPCLS, with the exception of Cryo 2 at day 1. A general concordance with WST-8 viability (Figure 3) was seen. Similar results were observed for AQ5 levels with no significant differences among the groups, N = 3/group per time point.